GlaxoSmithKline (GSK), facing a major bribery scandal in China, said yesterday that some of its executives in the country appeared to have broken the law.
“Certain senior executives of GSK China, who know our systems well, appear to have acted outside of our processes and controls which breaches Chinese law,” the British drugmaker’s head of emerging markets, Abbas Hussain, said in a statement.
Chinese authorities say GSK employees bribed government officials, pharmaceutical industry groups, hospitals and doctors to promote sales.
Photo: Reuters
Hussain, who was sent to China last week to lead GSK’s response to the crisis, held a meeting with the Chinese Ministry of Public Security at which he also promised to review GSK’s business model, leading to price reductions in the country.
Hussain apologized during the meeting on behalf of GSK, according to a ministry statement yesterday
“The GSK head office fully supports the determination and actions of the Chinese government in combating corruption,” he was quoted as saying.
A police official has previously claimed GSK staff funneled nearly US$500 million in suspected bribes through travel agencies and consultants since 2007.
Police have held four top executives of GSK China and prevented another, the firm’s British finance director, from leaving the country, though he has not been formally detained.
GSK executives also took kickbacks from travel agencies in return for organizing conferences, some of which did not exist, police say.
Media reports say more than 20 people have been detained in the case, including pharmaceutical and travel industry personnel.
Police in Shanghai have detained a British fraud investigator who did work for GSK, Peter Humphrey, Dow Jones Newswires reported on Sunday.
Meanwhile, GSK chief executive officer Andrew Witty will detail what action the drugmaker is taking in response to allegations of bribery against it in China when he presents quarterly results tomorrow, sources familiar with the matter said.
Although an internal company investigation has yet to conclude, people familiar with the matter said Witty would discuss what may have gone wrong in the scandal, which has rocked GSK’s reputation and left its management in China in disarray.
Britain’s biggest drugmaker, which has described the allegations against it in China as “shameful,” has already hired professional services firm Ernst & Young to conduct an independent review of its systems in the country and sent three senior executives to lead the response on the ground.
A company spokesman said it was also keeping all relevant regulators updated as appropriate.
The charges from China could expose GSK to prosecution under Britain’s Bribery Act and the US Foreign Corrupt Practices Act.
China’s economic planning agency yesterday outlined details of measures aimed at boosting the economy, but refrained from major spending initiatives. The piecemeal nature of the plans announced yesterday appeared to disappoint investors who were hoping for bolder moves, and the Shanghai Composite Index gave up a 10 percent initial gain as markets reopened after a weeklong holiday to end 4.59 percent higher, while Hong Kong’s Hang Seng Index dived 9.41 percent. Chinese National Development and Reform Commission Chairman Zheng Shanjie (鄭珊潔) said the government would frontload 100 billion yuan (US$14.2 billion) in spending from the government’s budget for next year in addition
Sales RecORD: Hon Hai’s consolidated sales rose by about 20 percent last quarter, while Largan, another Apple supplier, saw quarterly sales increase by 17 percent IPhone assembler Hon Hai Precision Industry Co (鴻海精密) on Saturday reported its highest-ever quarterly sales for the third quarter on the back of solid global demand for artificial intelligence (AI) servers. Hon Hai, also known as Foxconn Technology Group (富士康科技集團) globally, said it posted NT$1.85 trillion (US$57.93 billion) in consolidated sales in the July-to-September quarter, up 19.46 percent from the previous quarter and up 20.15 percent from a year earlier. The figure beat the previous third-quarter high of NT$1.74 trillion recorded in 2022, company data showed. Due to rising demand for AI, Hon Hai said its cloud and networking division enjoyed strong sales
TECH JUGGERNAUT: TSMC shares have more than doubled since ChatGPT’s launch in late 2022, as demand for cutting-edge artificial intelligence chips remains high Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday posted a better-than-expected 39 percent rise in quarterly revenue, assuaging concerns that artificial intelligence (AI) hardware spending is beginning to taper off. The main chipmaker for Nvidia Corp and Apple Inc reported third-quarter sales of NT$759.69 billion (US$23.6 billion), compared with the average analyst projection of NT$748 billion. For last month alone, TSMC reported revenue jumped 39.6 percent year-on-year to NT$251.87 billion. Taiwan’s largest company is to disclose its full third-quarter earnings on Thursday next week and update its outlook. Hsinchu-based TSMC produces the cutting-edge chips needed to train AI. The company now makes more
Protectionism: US trade chief Katherine Tai said the hikes would help to counter unfair trade practices from China, while boosting domestic clean energy investments US Trade Representative Katherine Tai (戴琪) defended stiff tariff hikes against countries such as China, saying that paired with investment, they were a “legitimate and constructive” tool for reinvigorating domestic industries. Tai’s comments come a week after sharp tariff increases on Chinese electric vehicles (EVs), EV batteries and solar cells took effect — with levies down the line on other products also recently finalized. The latest moves targeting US$18 billion in Chinese goods come weeks before next month’s US presidential election, with Democrats and Republicans pushing a hard line on China as competition between Washington and Beijing intensifies. In an interview on Thursday